Rheumatology

For Employers, Rheumatoid Arthritis Cost Overshadows Incidence

August 18th 2020

By Skylar Jeremias

Employers could save thousands of dollars by promoting the use of biosimilars that will keep employees with rheumatoid arthritis from having to file for disability, according to Brian Gifford, PhD, research director of the Integrated Benefits Institute.

ACCC's McBride on the Need for Biosimilar Education

August 18th 2020

By The Center for Biosimilars

Article

Ali Mcbride, PharmD, MS, BCOP, is taking a lead role in promoting the use and understanding of biosimilars in oncology.

Winegarden: Biosimilars Market Lacks Oomph

August 17th 2020

By Tony Hagen

Article

A Pacific Research Institute economist says that by his scorecard, biosimilars are not supercharging the market the way they ought to be doing .

Biosimilars Gain Market Share and Advocates Get Aboard

August 15th 2020

By Skylar Jeremias

Article

There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.

China Approves Henlius' Biosimilar Trastuzumab

August 14th 2020

By Tony Hagen

Article

Up-and-coming Henlius Biotech consolidates its footing in the biosimilar world with another regulatory approval.

Celltrion Refutes Critique of CT-P13 Equivalence

August 14th 2020

By Deana Ferreri, PhD

Article

Celltrion finds fault with a critique of equivalence margins used to approve its infliximab biosimilar.

Pfizer Expert Urges Employers to Get Proactive on Biosimilars

August 13th 2020

By Tony Hagen

Article

Defining biosimilar use in the United States as "sluggish," Juliana Reed, MS, said employers have to get involved.

Study to Evaluate Discontinuation of Biosimilar RA Treatment

August 11th 2020

By Tony Hagen

Article

Japanese investigators say more needs to be known about what happens post treatment with biosimilar infliximab in patients with rheumatoid arthritis (RA).

Polpharma Biologics: The Polish Biosimilar Powerhouse

August 11th 2020

By Skylar Jeremias

Article

Now that Polpharma Biologics has fully integrated Bioceros into its brand, the company hopes to become one of the world’s leading biologics manufacturers.

Study: How Out-of-Pocket Caps Affect Payer Policy

August 7th 2020

By Tony Hagen

Article

Investigators set out to learn whether the imposition of out-of-pocket spending caps on specialty drugs would unleash a wave of drug spending and prompt payer policy change.